Shots:
- Teva has entered into a funding agreement with Royalty Pharma to accelerate the clinical development of Teva’s TEV-’408 for the treatment of vitiligo
- As per the deal, Teva will receive ~$500M to support TEV-‘408 development costs, incl. $75M in R&D co-funding for a P-IIb study planned for 2026. Royalty will have an option to provide an additional $425M to co-fund P-III trial based on P-IIb results, with Teva paying milestones & royalties upon approval
- TEV-‘408 is an anti-IL-15 mAb in P-Ib trial for vitiligo & P-IIa for celiac disease, with Teva planning to report clinical results from these studies in 2026
Ref: Globenewswire | Image: Teva & Royalty Pharma | Press Release
Related News: Alvotech and Teva Enter into an Agreement with Regeneron to Launch AVT06 (Biosimilar, Eylea) Across US
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
